Modality
ERT
MOA
MDM2i
Target
Tau
Pathway
T-cell
Thymoma
Development Pipeline
Preclinical
~Feb 2017
→ ~May 2018
Phase 1
~Aug 2018
→ ~Nov 2019
Phase 2
Feb 2020
→ Dec 2026
Phase 2Current
NCT04339535
1,211 pts·Thymoma
2020-02→2026-12·Active
NCT07168227
213 pts·Thymoma
2024-05→TBD·Terminated
1,424 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-12-028mo awayPh2 Data· Thymoma
Trial Timeline
2020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q4
P2
Active
P2
Termina…
Catalysts
Ph2 Data
2026-12-02 · 8mo away
Thymoma
ActiveTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04339535 | Phase 2 | Thymoma | Active | 1211 | ORR |
| NCT07168227 | Phase 2 | Thymoma | Terminated | 213 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Doxacapivasertib | Eli Lilly | Phase 3 | APOC3 | |
| BMY-8678 | Bristol-Myers Squibb | Approved | RET | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| TAK-8262 | Takeda | NDA/BLA | Tau | |
| AMG-415 | Amgen | Phase 1 | CDK2 | |
| GIL-2037 | Gilead Sciences | Approved | KRASG12D | |
| Capiglumide | BioNTech | Preclinical | CGRP | |
| Rimasertib | Exelixis | Phase 3 | B7-H3 | |
| 180-6098 | Innovent Bio | Phase 1 | ALK |